BeiGene
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| Revolution Medicines (RVMD) | 34.87B | -17.66 | 14.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 5.6% below Morningstar's fair value estimate.
Fair value
BeOne Medicines Ltd earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% discount to our quantitative fair value estimate of $412.74 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The firm's solid growth increases our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 40.9% falls in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.
Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 10.8%, a core component of profitability, sits in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BeiGene discussion 0 comments